Semaglutide(Zhejiang Apeloa Kangyu)

Primary objective: Using semaglutide injection (trade name: Novo Nordisk®) produced by Novo Nordisk A/S as the reference drug and semaglutide injection provided by Zhejiang Proconyu Pharmaceutical Co., Ltd. as the test drug, a single-center, randomized, open, two-formulation, single-dose, parallel-design PK comparative study was conducted to evaluate the pharmacokinetic similarity of the two formulations in healthy Chinese subjects after subcutaneous injection. Secondary objective: To evaluate the safety and immunogenicity of the two formulations in healthy Chinese subjects.